BioNTech SE - American Depositary Shares (NQ:BNTX)

96.62 -0.28 (-0.29%)

Delayed Quote Updated: 11:51 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

73 74 Next >

Pfizer (PFE) Stock Falls on Analyst Downgrade ↗

January 17, 2023

Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock.

Via InvestorPlace

Pfizer Stock Dives As Analyst Calls For 'Covid Reset' And Downgrades Shares ↗

January 17, 2023

Shares have skidded almost 10% in the first two weeks of 2023.

Via Investor's Business Daily

US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People ↗

January 16, 2023

The U.S.

Via Benzinga

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing” ↗

January 12, 2023

Small-cap speculative biotech stocks regain interest with volatility.

Via Talk Markets

BioNTech Starts Dosing In Herpes Vaccine Candidate Study ↗

December 21, 2022

Via Benzinga

Will Investors Notice Exciting Sign On BioNTech's Chart? ↗

December 19, 2022

Via Benzinga

BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British Startup ↗

January 10, 2023

Via Benzinga

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

January 10, 2023

From BioNTech SE

Via GlobeNewswire

Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly ↗

January 09, 2023

Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients.

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

2 Top Biotech Stocks to Buy Right Now ↗

January 06, 2023

These two pharmaceutical companies pay market-beating dividends to shareholders.

Via The Motley Fool

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

January 05, 2023

From BioNTech SE

Via GlobeNewswire

Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study ↗

January 03, 2023

Via Benzinga

Why BioNTech Was a Sickly Stock This Week ↗

December 30, 2022

The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks.

Via The Motley Fool

BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 28, 2022

From BioNTech SE

Via GlobeNewswire

Three Pharma Stocks to Sell Before They Die ↗

December 24, 2022

As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.

Via InvestorPlace

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

December 23, 2022

From BioNTech SE

Via GlobeNewswire

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

December 22, 2022

From BioNTech SE

Via GlobeNewswire

Update on First BioNTainer for African-based mRNA Manufacturing Facility

December 21, 2022

From BioNTech SE

Via GlobeNewswire

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

December 21, 2022

From BioNTech SE

Via GlobeNewswire

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗

December 18, 2022

These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.

Via InvestorPlace

Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review ↗

December 16, 2022

Moderna spiked on a cancer vaccine while Tesla continued to dive.

Via Investor's Business Daily

BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities ↗

December 15, 2022

Via Benzinga

Why Is Novavax (NVAX) Stock Plunging Today? ↗

December 15, 2022

NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player.

Via InvestorPlace

Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry ↗

December 13, 2022

At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.

Via Benzinga

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off ↗

December 13, 2022

Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.

Via Investor's Business Daily

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

December 09, 2022

From BioNTech SE

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗

December 15, 2022

Via Benzinga

FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old ↗

December 08, 2022

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.